Beyond Omicron | Harvard Medical School
Antibodies and COVID-19 | CDC
Frontiers | Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment? | Microbiology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review | Molecular Cancer | Full Text
NIH scientists identify mechanism that may influence infectivity of SARS-CoV-2 variants | National Institutes of Health (NIH)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor - ScienceDirect
NIH researchers identify key genomic features that could differentiate SARS- CoV-2 from other coronaviruses that cause less severe disease | National Institutes of Health (NIH)
SARS-CoV-2 Coronavirus and COVID-19
Why does SARS-CoV-2 spread so easily?
SARS-CoV-2: What's in a Name?
Prion-like domains in SARS-CoV-2 RBD and ACE2 play important functional roles in viral adhesion and entry
Review summarises liver injury from human coronavirus infections, including SARS-CoV-2 - EASL-The Home of Hepatology.
FluoroType® SARS-CoV-2 plus | Bruker
The mysterious disappearance of the first SARS virus, and why we need a vaccine for the current one but didn't for the other
Coronaviruses Have Been Around For Centuries: What Differentiates COVID-19? – Consult QD
An Update on the Perioperative Considerations for COVID-19 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) - Anesthesia Patient Safety Foundation
Cureus | Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2
Diagnostics | Free Full-Text | Laboratory Diagnosis of SARS-CoV-2 Pneumonia
Why some individuals have stronger SARS-COV-2 defences – UKRI
Novel coronavirus structure reveals targets for vaccines and treatments | National Institutes of Health (NIH)
coronavirus | Definition, Features, & Examples | Britannica
Getting to know the new coronavirus - Coronavirus: the science explained - UKRI
Discovery of shape of the SARS-CoV-2 genome after infection could inform new COVID-19 treatments | University of Cambridge
A Visual Guide to the SARS-CoV-2 Coronavirus - Scientific American
Cancer Drug Shows Potent Activity in the Lab Against SARS-CoV-2, Including B.1.1.7 Variant | UC San Francisco
SARS-CoV-2 (2019-nCoV) Proteins | BioVendor R&D
